ClinicalTrials.gg
RecruitingNCT04772170Updated Sep 9, 2026

Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies

An observational study in Influenza, Respiratory Virus and Coronavirus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID) — 11 open to participants now, 12 under way, none of them phase 3. Influenza, Human · National Institute of Allergy and Infectious Diseases (NIAID).

Planned enrollment
5th of 20
1,000 · median 190
Started
2023
with 4 others
Observational
20 of 186
4 open now
Primary completion
2027-06
later than 5 of 10 live
Registered
166th of 186
by date

Among the 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 5th largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2023, is one of 20 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 166th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

11 of the 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

Background:

Respiratory viruses circulate throughout the year and around the globe. Wearable and sensor devices, like smartwatches, may be able to help monitor infectious diseases. Researchers want to use them to learn how respiratory viruses affect people in different ways.

Objective:

To use digital devices to collect data from participants in challenge studies that could indicate subtle changes in health during an infection that might otherwise go unnoticed.

Eligibility:

Healthy adults who have enrolled, were recently enrolled, or are scheduled to enroll in a challenge study.

Design:

Participants will stay at NIH for the duration of the challenge study (at least 9 days) and then will have outpatient follow-up visits (2-4).

While at NIH, participants will wear a smartwatch at all times. It will record data like temperature, heart rate, breathing rate, and movements.

Participants will have a smartphone that records at all times to listen for coughing and changes in voice.

Participants will perform tasks every 4 hours during the daytime. They will record themselves coughing, breathing in deeply, and reading aloud. They will take videos of their face. They will play a game to test their reflexes and focus. They will measure their head temperature with their smartwatch.

For outpatient visits, participants will use one smartphone and the smartwatch to complete the above tasks.

Participants will be sent a smartwatch to wear at home at night to collect additional healthy data.

Participation will last the duration of each challenge study, and may range from 10 weeks to 2 years.

Read the detailed description

Study Description:

Wearable and sensor digital devices have the potential to be important tools in infectious diseases surveillance. In this study, digital devices will be used to evaluate responses before and after respiratory virus challenge on a separate NIH protocol. Participants recently enrolled, currently enrolled, or planned for enrollment in a challenge study are eligible. Devices will be worn and/or used during the inpatient hospitalization and at outpatient follow-up visits. Participants may be sent smartwatches at home to collect additional baseline or healthy data. Devices may collect data on coughing, speech, heart rate, heart rhythm, sweating, and temperature to identify digital biomarkers associated with respiratory virus infection. The correlation between digital device measurement data and clinical data, particularly on cough, will be determined. We hypothesize that sensor-collected data will correlate with symptom severity obtained by clinician assessment and participant report. We also hypothesize that digital biomarkers can predict influenza infection and can be used to develop a predictive model.

Objectives:

  • Primary:

    1. To correlate continuous cough sensor data to cough severity after challenge.
    2. To develop a predictive model for mild-moderate influenza disease (MMID) and influenza infection using digital biomarkers
  • Secondary: To correlate continuous and noncontinuous vital sign sensor data to routine vital signs obtained by clinical staff.
  • Exploratory:

    1. To evaluate body sensor data after challenge.
    2. To correlate digital biomarker data to biological biomarker data.

Endpoints:

Primary:

  1. Cough quantity:

    -Continuous cough measurements

  2. Infection

    • Defined as:

      • MMID (positive PCR for influenza and >=1 symptoms)
      • Flu (positive PCR for influenza or convalescent four-fold increase in serum antibodies to the hemagglutinin (HA) or neuraminidase (NA) of the challenge virus and >=1 symptoms)
      • Influenza infection (positive PCR for influenza)
    • Using predictor variables such as:

      • Smartwatch photoplethysmography (PPG) determined heart rate
      • Smartwatch electrodermal activity (EDA) determined sweating
      • Smartwatch determined temperature
      • Smartwatch Electrocardiogram (ECG) monitoring
      • Audio voice recording

    Secondary: Vital signs:

  3. Heart rate
  4. Respiratory rate
  5. Temperature

Exploratory:

Correlations between digital biomarker data and biological biomarker data (e.g. antibody titers)

03

Conditions studied

  • Influenza
  • Respiratory Virus
  • Coronavirus

Keywords

  • Wearable Digital Device
  • Bed Sensor
  • Smartphone
  • Cough Count
  • Smartwatch
  • Natural History
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy volunteers currently enrolled in a respiratory virus challenge study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Able to provide .
  2. Current, recent, or planned enrollment in a respiratory virus challenge study at the NIH Clinical Center.
  3. Willing to wear devices as instructed.
  4. Willing to participate in monitoring activities as instructed.
  5. Willing to have monitoring data stored.
  6. Willing to have monitoring data shared with protocol investigators at NIH, University of Washington, and University of Toronto.
  7. Willing to have select clinical data from the challenge study such as vital signs, viral shedding, pulmonary function test and/or spirometry results, and clinical symptoms data shared with investigators at University of Washington and University of Toronto.

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Any condition that, in the opinion of the investigator, contraindicates participation in this study.

Co-enrollment guidelines: Participants must be co-enrolled, planned for co-enrollment, or recently enrolled in a challenge study. Co-enrollment in other studies is restricted but may take place after study staff notification and only with approval of the principal investigator or designee.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)

Groups and cohorts

  • Current Challenge Study Participant

    Current participation in a respiratory virus challenge study at the NIH CC

06

What researchers measure

Primary outcomes

  1. To correlate continuous cough sensor data to cough severity after challenge.To develop a predictive model for MMID and asymptomatic influenza infection using digital biomarkers.

    Cough is a known symptom of respiratory virus infections and can be quantified by objective measurements.Data from smart devices may be able to discern who gets sick with a respiratory virus and could be utilized as a diagnostic tool.

    Time frame: minimum of 9 days inpatient

Secondary outcomes

  1. To correlate continuous and noncontinuous vital signs sensor data to routine vital signs obtained by clinical staff.

    Vital signs are routinely measured in challenge studies and are also routinely collected from digital devices. Vital sign changes can be associated with respiratory virus infections.

    Time frame: minimum of 9 days inpatient

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contactprpl@cc.nih.gov · 800-411-1222
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Jun 2027, 43 months after the start.

Of 98 non-industry observational studies under Influenza, Human, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 92. This study's planned 43 months is above that.

Counting every sponsor, half of 135 studies reached it within 23 months; a quarter within 7 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2021
First posted
Feb 26, 2021
StartActual
Oct 23, 2023
Primary completionEst.
Jun 2, 2027
CompletionEst.
Jun 2, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04772170
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
Oct 23, 2023
Primary completion
Jun 2, 2027 (estimated)
Completion
Jun 2, 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Rani S Athota, Ph.D.
Contact
rani.athota@nih.gov
(301) 594-0803
Luca T Giurgea, M.D.
Contact
luca.giurgea@nih.gov
(301) 538-5235
Luca T Giurgea, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion